• Strategic partnership established with Sigma | Chemist Warehouse
• Pharmx Marketplace launched in November 2025, delivering record GTV
• Strong adoption of Pharmacy Portal with over 1,200 pharmacies live

Pharmx Technologies Ltd, an ASX-listed pharmacy technology provider, has reported its results for the first half of the 2026 financial year. The company achieved a 3% increase in total revenue to $3.9 million, despite an intentional pause on onboarding new suppliers until the launch of its new Marketplace platform in November 2025. Gateway revenue increased by 5% compared to the prior corresponding period, while Marketplace revenue grew by 24%. The company also reported a 54% increase in revenue from New Zealand, reflecting its continued strong performance in that market. Pharmx's gross margin improved by 2 percentage points to 84%, and its 'Base Business' EBITDA increased by 23% on the prior corresponding period, before the impact of growth initiatives. The company reported a positive EBITDA of $0.5 million, a decrease of $0.5 million compared to H1 FY25. This was due to increased costs related to growth initiatives and the launch of the Marketplace platform, including higher personnel costs, investment in technology and IT infrastructure, and increased marketing activity. The company also saw increases in amortization and share-based payments. Pharmx ended the period with a strong cash balance of $3.2 million and positive operating cash flows of $0.2 million. The company highlighted several key strategic developments during the period, including the establishment of a multi-year strategic partnership with Sigma | Chemist Warehouse, which appointed Pharmx as a preferred EDI and growth partner. Pharmx also launched its Marketplace platform in November 2025, which delivered record GTV in December, up 68% compared to the prior peak. The company also continued to see strong adoption of its Pharmacy Portal, with over 1,200 pharmacies live on the platform as of December 2025. Pharmx remains focused on cost discipline, with engineering team reductions implemented following the launch of its Single Platform. The company also continued its international expansion, with strong growth in New Zealand under the Sigma Strategic Alliance.

Pharmx Technologies Ltd has not provided any specific forward-looking financial guidance for the 2026 financial year.

Pharmx Technologies Ltd has not provided a detailed outlook statement. However, the company has highlighted the strategic importance of its partnership with Sigma | Chemist Warehouse, which is expected to materially change the profile of the Pharmx business by securing its core business, validating and accelerating its Single Platform strategy, and providing opportunities for vertical and international expansion.